Biotech & Pharma rNPV Valuation Model Excel – 20-Year Drug Pipeline DCF, Clinical PoS & Funding

Financial Model, Health Care, Life Science, Pharmacies & Drugstores

Business Valuation, Cash Flow Analysis, Cash Flow Projections, Chart, Cost Projections, Dashboard, DCF Model, Discount Rate, Excel, Financial Analysis, Financial Feasibility, Financial Model, Financial Modeling, Financial modelling, Financial Planning, Financial Projections, Financial Reporting, Financial Statements, Financing, Forecast, Forecasting, Fundraising, Income Statement, Investors, KPIs (Key Performance Indicators), NPV (Net Present Value), Profitability Analysis, Revenue Projections, Risk-Adjusted NPV, Scenario Analysis, Sensitivity Analysis, Startup Financial Models, Three Statement Model | Three Financial Statements, Valuation

20-Year Risk-Adjusted DCF / rNPV | Clinical Pipeline | Funding & Equity Dilution

Value drug development programs, assess clinical risk and translate a multi-asset pipeline into transparent financial and financing forecasts.

The Biotech & Pharma Valuation Model – Signature Edition by SheetworksStudio is an integrated, editable Excel valuation system for biotechnology founders, pharmaceutical finance teams, corporate-development professionals, analysts, investment teams and life sciences advisors.

The workbook combines phase-specific Probability of Success (PoS), development spending, product commercialization, licensing terms, company financial forecasts, a five-year monthly funding plan and equity dilution into one connected framework.

Instead of applying a blanket clinical haircut, risk-adjusted research spending is weighted by the probability of reaching future stages and commercial revenues by the modeled probability of approval.

The purchase includes 16 Excel worksheets, 15 illustrative drug candidates, 20 annual forecast periods, 60 months of cash-runway planning, three operating scenarios, eight Excel dashboard charts and a 26-page PDF handbook.

🧬 CLINICAL PIPELINE & RISK-ADJUSTED VALUATION

Analyze 15 individual drug candidates with editable development-stage, modality, therapeutic area, risk calibration and commercial assumptions.

Key features include:

• Preclinical, Phase I, Phase II, Phase III, NDA/BLA and Approved stages
• Conditional stage-transition PoS and cumulative approval probability
• Candidate-level clinical probability adjustments
• Stage duration, remaining R&D spending and expected launch timing
• Patent expiration and post-exclusivity revenue erosion
• Discounted risk-adjusted cash flow and asset rNPV
• Unrisked NPV comparisons and consolidated pipeline valuation

The CLINICAL POS worksheet contains historical benchmark rates and source notes.

These clinical probability assumptions must be independently reviewed and adapted to the relevant therapeutic indication and development program.

💊 COMMERCIALIZATION & LICENSING ECONOMICS

Select Direct Commercialization or Licensing for each drug candidate.

Direct Commercialization

Model eligible patient populations, annual net treatment price, peak market penetration, commercial adoption ramp, annual price growth, product costs, selling expenses and patent-expiry erosion.

Licensing

Model upfront payments, approval and sales milestones, sales-trigger assumptions and recurring royalty economics.

Contingent income is weighted according to the workbook’s clinical probability conventions.

Each asset feeds into the 20-year investment forecast and consolidated portfolio calculations.

📊 FINANCIAL FORECASTS & INVESTMENT DASHBOARD

The model provides 20 annual periods, with illustrative years 2029–2048, and an editable starting year.

The financial framework includes:

• Risk-adjusted direct product sales and licensing receipts
• Clinical research and development spending
• Cost of goods sold and commercial SG&A
• Corporate G&A, CAPEX and depreciation
• Working capital and simplified corporate taxation
• Income Statement, Balance Sheet and Cash Flow Statement
• Enterprise risk-adjusted valuation and indicative equity value

Executive Dashboard – 8 Dynamic Charts

The dashboard presents essential valuation, operational and financing indicators:

• Pipeline Asset rNPV
• Enterprise rNPV
• Indicative Equity Value
• Active Drug Candidates
• Five-Year Clinical Spending
• Additional Funding Need
• New Equity Dilution
• Funded Cash Runway

Eight native Excel charts visualize the underlying financial and clinical development calculations.

All reported values are illustrative financial model outputs, not guaranteed investment or clinical outcomes.

💰 60-MONTH FUNDING, CASH RUNWAY & DILUTION

Follow monthly liquidity requirements during the first five years.

The financing module includes:

• Monthly opening and closing cash balances
• Planned clinical development expenditure and corporate G&A
• Minimum liquidity reserves
• Scheduled financing rounds
• Equity issue prices and newly issued shares
• Shareholder dilution
• Additional funding requirements
• Funded and unfunded cash runway analysis
• Financing register prepared for up to 500 events

The liquidity forecast uses a conservative planned-spending approach rather than assuming all clinical research expenditure can be reduced by the probability of success.

Important: Funding requirements relate to the selected 60-month period. Clinical development delays may shift expenditure beyond that window, reducing near-term funding requirements without eliminating future financing risk.

🔄 BASE, UPSIDE & DOWNSIDE SCENARIOS

Change the active scenario in CONTROL CENTER to evaluate alternative clinical, commercial and financial conditions.

BASE CASE

Central illustrative clinical development, commercialization and financing assumptions.

UPSIDE CASE

Improved clinical probabilities, stronger commercial potential and more favorable development economics.

DOWNSIDE CASE

Lower success probabilities, weaker sales assumptions, additional R&D spending and delayed development.

Valuation Sensitivity

A 5 × 5 Enterprise rNPV sensitivity matrix examines changes in discount rates and peak commercial sales assumptions.

The sensitivity matrix holds selected clinical development and licensing inputs fixed. Broader scenario changes can be evaluated through the live scenario controls.

⚙️ PROFESSIONAL WORKBOOK STRUCTURE

The Excel model includes 16 integrated worksheets:

1. START HERE – Setup and navigation
2. EXECUTIVE DASHBOARD – KPIs and eight charts
3. CONTROL CENTER – Scenario and company assumptions
4. CLINICAL POS – Stage probabilities and benchmarks
5. DRUG PIPELINE – Fifteen asset records
6. TRIAL BUDGETS – Development timing and budgets
7. COMMERCIAL INPUTS – Patient, pricing and licensing assumptions
8. ASSET ENGINE – Clinical probability and asset valuations
9. ASSET CASH FLOWS – Risk-adjusted program cash flows
10. PORTFOLIO CF – Consolidated portfolio economics
11. FINANCIAL STATEMENTS – Twenty-year three-statement forecast
12. FINANCING & RUNWAY – Monthly liquidity and equity events
13. VALUATION SENSITIVITY – Discount rate and sales stress testing
14. CHART DATA – Linked dashboard series
15. MODEL CHECKS – Twenty calculation controls
16. USER GUIDE & SOURCES – Instructions and references

Built-In Model Checks

The MODEL CHECKS worksheet provides 20 formula-driven controls addressing clinical assumptions, financial reconciliations, valuation links, cash balances, financing entries and forecast structure.

Passing a model-integrity check does not certify clinical assumptions, future regulatory outcomes or the financial feasibility of a transaction.

📦 WHAT YOU RECEIVE

1. Biotech & Pharma rNPV Financial Model (.xlsx)

A fully editable 16-worksheet Excel workbook with:

• 15 illustrative drug development programs
• 20-year annual forecasting
• 60-month liquidity analysis
• Three financial scenarios
• Eight executive dashboard charts
• Direct commercialization and licensing economics
• Financial statements and enterprise valuation
• Funding and dilution analysis
• Twenty model validation controls

2. Professional How-to-Use Guide – 26-Page PDF

A detailed English manual covering:

• Workbook setup and navigation
• Clinical probability methodology
• Drug pipeline assumptions
• Trial durations and development budgets
• Commercialization and licensing economics
• Financial statement interpretation
• Company and asset rNPV
• Equity funding and dilution
• Cash runway
• Scenario and sensitivity analysis
• Model validation and troubleshooting
• Clinical probability sources and glossary

The handbook contains 24 chapters, practical cell references and a final review checklist.

3. Illustrative Sample Data

Fictional drug candidates, clinical assumptions, commercial terms, financial figures and financing events demonstrate the complete valuation workflow.

IDEAL FOR

• Biotechnology Founders and CFOs
• Pharmaceutical Finance Teams
• Life Sciences Investors
• Healthcare and Biotechnology Investment Analysts
• Business Development and Licensing Professionals
• Pharmaceutical Portfolio Managers
• Corporate Development and M&A Teams
• Financial Modeling Consultants
• Specialist Finance and Biotechnology Students

Typical use cases include pipeline valuation, fundraising preparation, licensing analysis, biotech company forecasting, portfolio reviews and scenario analysis.